Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck develops potent, short-acting, orally active GH secretagogues

March 31, 1999

Potent new SERM related to raloxifene presented at ACS meeting by Lilly

March 31, 1999

Ono discloses PPARgamma modulators for metabolic disorders

March 31, 1999

Postmenopausal syndrome continues as focus of R&D at Lilly

March 31, 1999

Preclinical studies support BM-17.0744 as a potential treatment for metabolic syndrome

March 30, 1999

Hemosol product advances; company receives milestone payment from Fresenius

March 30, 1999

Lilly's new agents for lipid disorders act by increasing HDL cholesterol levels

March 30, 1999

FDA approves Duramed's Cenestin for treatment of menopause symptoms

March 29, 1999

Patent issued to Pfizer for NPY antagonist series

March 29, 1999

Droloxifene plus PGE2 effectively restores and maintains bone mass

March 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...